K. Schindler

Oncology · 2015–2016

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom K. Schindler trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Wolchok (in Oncology)

Papers from K. Schindler's perspective

Ordered by how strongly the researchers K. Schindler trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  6. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  7. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  8. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (Journal of Clinical Oncology)
  9. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
  10. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)

Their papers